Omesdafexor (MET409) is a small-molecule farnesoid X receptor (FXR) agonist developed for nonalcoholic steatohepatitis and colitis.[2][3]
Clinical data | |
---|---|
Other names | MET409[1] |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C34H43N3O3 |
Molar mass | 541.736 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ https://www.journal-of-hepatology.eu/article/S0168-8278(21)00099-4/abstract
- ^ Liu, Xueqing; O'Connell, Robert; Bendele, Alison; Walker, Melissa; Ohlsen, Connor; Govek, Steve; Nagasawa, Johnny; Douglas, Karensa; Milik, Angelica; Lu, Nhin; Qian, Jing; Ortiz, Alvaro; Chai, Pauline; Zook, Douglas; Lee, Kyoung-Jin; Smith, Nicholas; Wagner, Brandee; Song, Ken (February 2020). "P153 Met642, an Oral FXR Agonist, Improves Colitis Induced by Adoptive T-Cell Transfer". Gastroenterology. 158 (3): S11. doi:10.1053/j.gastro.2019.11.062.
- ^ "Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients". Retrieved 2 December 2023.